GLP-1 Pharmacovigilance
Sex-stratified signal detection across 18.5M+ FDA adverse event records using disproportionality analysis for GLP-1 receptor agonists.
Biomedical Informatics · Healthcare Analytics · Life Sciences Strategy
I combine clinical context, analytical methods, and product thinking to build tools for real-world evidence, patient access, and healthcare operations. I also work at the strategy layer, translating analytical findings into business cases and decisions.
Education
UPenn MBMI
Master of Biomedical Informatics
GPA 3.81 / 4.00
Scholarship
LPDP Scholar
Full-ride merit scholarship
LPDP · Ministry of Finance of Indonesia
Research Scale
158K+
Distinct GLP-1 cases analyzed
Sex-stratified pharmacovigilance
Signal Detection
665
Multiple-testing-adjusted safety signals detected
FAERS · ROR · PRR
Partnerships
200+
Hospital and clinic agreements secured
Leadership
Executive-Facing
Weekly insights presented to the CEO and Hospital Director
Selected impact across research, healthcare operations, and analytical systems
18.5M+
FAERS records harmonized
216%
Referral revenue growth
45.5%
Reduction in EMR-related processing time
70%
Reduction in laboratory analysis time
Selected Work
I build analytical systems that translate complex biomedical and healthcare data into evidence, operational insight, and usable decision support.
Sex-stratified signal detection across 18.5M+ FDA adverse event records using disproportionality analysis for GLP-1 receptor agonists.
An analytical product translating clinical questions into cohort definitions, generated queries, and interpretable evidence outputs.
Economic modeling, payer segmentation, and scenario analysis for a healthcare AI business case, conducted through the Penn Graduate Consulting Club.
Reproducible Python pipeline for gene-level association scoring, normalization, and relative tier assignment from MAGMA or GWAS summary statistics.
BMIN 5030: Data Science for Biomedical Informatics course project examining selected access and socioeconomic variables associated with reported HPV vaccine receipt in NHANES 2021-2023 data.
Selected case studies are being expanded. Reach out to learn more.